India's Wockhardt faces U.S. failure-to-warn claims for reference generic; China raps drug, device makers over ads;

> The U.S. Supreme Court lets stand a Pennsylvania appeals court decision that Indian generic drug company Wockhardt must face failure-to-warn claims in state court over a reference product. Story

> Germany's Evotec AG in multitarget screening collaboration on ion channel targets, with Japan's Asahi Kasei Pharma. Release

> Astellas and Medivation ($MDVN) announce new data from the Phase II trial of enzalutamide compared to bicalutamide in metastatic castration-resistant prostate cancer. Release

> CASI Pharmaceuticals ($CASI) announced a Phase II trial of its target therapy drug candidate ENMD-2076 in triple-negative breast cancer at the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing. Release

> Zimmer Holdings ($ZMH) won approval from the Japan Fair Trade Commission to buy Biomet. Release

> China FDA raps domestic drug and device companies over false advertising claims. Release (Chinese)